ON-DEMAND WEBINAR Immuno-Oncology in Humanized Mice
The approval in 2011 of the first immune-checkpoint inhibitor has validated the immune-therapy approach against many cancers. The reconstitution of a fully functional human immune system in the NOG mouse (huNOG) provides a unique opportunity to assess the efficacy of new drug candidates acting on both human immune cells such as T cells, myeloid cells and NK cells, and on the tumor itself.
This webinar reports on different tumor cell line growth and/or patient-derived xenograft models successfully engrafted in the huNOG models. We also show infiltration of human immune cells in the tumors. Furthermore, checkpoint inhibitors such as anti-PD1 strongly reduced tumor growth in huNOG demonstrating the usefulness of this model in onco-immunology. Transgenic NOG mice have been further developed to boost the differentiation of myeloid and NK cells, allowing scientists to efficiently test new antibodies or small molecules targeting those immune cell populations.
Dr. Patrick Nef is Chief Executive Officer and Founder at TransCure bioServices SAS. He holds a PhD in Molecular Neurobiology from the University of Geneva, Switzerland. He has more than 30 years of experience as Assistant Professor at the Univ. of Geneva, Vice-Director at F. Hoffmann-La Roche, ltd, Basel and CSO, CBO and CEO for several biotechnology driven companies. In 2012, he founded TransCure bioServices SAS. Patrick Nef has published more than 50 peer-reviewed publications and patents in the field of sensory olfaction, learning and memory, and calcium sensors.
Dr. Sebastien Tabruyn is Chief Scientific Officer at TransCure bioServices SAS. He holds a PhD in Molecular Biology from the University of Liege (Belgium). After 10 years of experience as project leader in renowned international academic research institutes including UCSF (California, USA), the Centre for Cancer Biology (Adelaide, Australia) and the University of Maastricht (Netherlands), he joined TransCure bioServices in 2013 as Head of Molecular Biology and Oncology. Sebastien Tabruyn has published 30 peer-reviewed publications in the fields of oncology, angiogenesis and inflammation.
Expect to Learn:
How humanized immune system mice can be applied to immuno-oncology drug discovery
How humanized mice can be engrafted with cell line and PDX tumors
How checkpoint inhibitors can be profiled in humanized mice
How humanized mice can be used in immuno-oncology studies targeting different human cell populations